Esperion Therapeutics Inc... (ESPR)
NASDAQ: ESPR
· Real-Time Price · USD
2.13
0.06 (2.90%)
At close: Aug 15, 2025, 12:03 PM
Esperion Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -40.45M | -21.32M | -29.52M | -61.92M | 61.02M | -56.34M | -41.25M | -49.94M | -61.72M | -55.49M | -55.12M | -66.32M | -56.73M | -65.12M | -69.39M | -43.67M | -90.94M |
Depreciation & Amortization | 725K | 27K | -411K | 10K | 437K | 6K | 26K | 51K | 81K | 92K | 105K | 150K | 153K | 153K | 153K | 153K | 153K |
Stock-Based Compensation | 2.46M | 2.81M | 3.02M | 2.93M | 3.23M | 2.92M | 2.98M | 3.16M | 2.9M | 3.71M | 3.54M | 3.53M | 4.44M | 4.47M | 5.5M | 8.58M | 5.75M |
Other Working Capital | -9.83M | -3.9M | 3.45M | -7.22M | -4.76M | 18.51M | 12.51M | 13.38M | 5.79M | 1.21M | -4.84M | 10.64M | -4.38M | -672K | 2.48M | 2.44M | 881K |
Other Non-Cash Items | 2.61M | 4.84M | 4.01M | 56.78M | 11.37M | 29.89M | 12.35M | 11.89M | 11.4M | 11.42M | 11.67M | 11.81M | 11.59M | 11M | 10.86M | 8.34M | 5.33M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -17.49M | n/a | -73K | n/a | n/a | n/a | n/a | n/a | -2.63M | n/a | n/a | n/a |
Change in Working Capital | 12.03M | -21.31M | -12.42M | -5M | -21.8M | 3.96M | 6.58M | 10.16M | -7.02M | -2.21M | -3.03M | 301K | 1.57M | -5.58M | -16.29M | -21.28M | -9.36M |
Operating Cash Flow | -22.63M | -34.95M | -35.33M | -7.21M | 53.83M | -37.06M | -19.32M | -24.75M | -54.36M | -42.47M | -42.83M | -50.53M | -38.99M | -57.71M | -69.17M | -47.87M | -89.07M |
Capital Expenditures | n/a | n/a | -167K | -77K | -73K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -41.8M | n/a | n/a | -18.1M | -50.48M | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 17.5M | 25M | 30M | 33M | 5M | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | -42.5M | n/a | 17.5M | 25M | -11.79M | 33M | 5M | -18.1M | -50.48M | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | -167K | -77K | -73K | n/a | n/a | 17.5M | 25M | -11.79M | 33M | 5M | -18.1M | -50.48M | n/a | n/a | n/a |
Debt Repayment | n/a | 35.01M | -9.63M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | -343.75M | n/a | n/a | -20K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -7.5M | n/a | n/a | -30.02M | -66K | -47.96M | 48.15M | 809K | -3.11M | -52.35M | -2.36M | -2.1M | -1.44M | -890K | -733K | 49.11M | 2.04M |
Financial Cash Flow | -7.5M | 35M | -9.1M | -30.02M | 90.61M | 4.47M | -4.31M | 809K | 49.49M | -30.36M | 46.29M | 18.11M | -1.44M | 213.41M | 3.65M | 49.11M | 2.04M |
Net Cash Flow | -30.13M | 44K | -44.59M | -37.3M | 144.36M | -32.59M | -23.64M | -6.44M | 20.14M | -84.62M | 36.46M | -27.42M | -58.53M | 105.22M | -65.51M | 1.25M | -87.02M |
Free Cash Flow | -22.63M | -34.95M | -35.49M | -7.28M | 53.76M | -37.06M | -19.32M | -24.75M | -54.36M | -42.47M | -42.83M | -50.53M | -38.99M | -57.71M | -69.17M | -47.87M | -89.07M |